# An exciting panel including Jan Schlender and Gunther Jansen, PhD of Novartis , Petrina Kamya, P...

> I attended an exciting panel on GenAI's impact in preclinical development, featuring voices from Novartis, Insilico Medicine, and INVIDIA. Key themes included the balance of AI opportunity and risk, the power of robotics combined with AI, and the ongoing challenge of data organization and institutional memory in the lab.

URL: https://www.ch-healthtech.com/insights/exciting-panel-including-jan-schlender-gunther-jansen-phd-novartis-petrina-kamya
Markdown: https://www.ch-healthtech.com/insights/exciting-panel-including-jan-schlender-gunther-jansen-phd-novartis-petrina-kamya.md
Published: 2025-10-06
Updated: 2026-05-06
Author: Christian Hein
Tags: technology/generative-ai, technology/machine-learning, technology/in-silico-clinical-trials, function/innovation-management, industry/large-pharma, industry/biotech, function/pre-clinical-research

---


An exciting panel including Jan Schlender and Gunther Jansen, PhD of Novartis , Petrina Kamya, Ph.D. Of Insilico Medicine, David Ruau of INVIDIA, moderated by Ivana Knyght, on GenAI's impact in preclinical development.

Some key insights:

- Phase III won't go away any time soon as we need the final validation. But there is plenty of opportunity in the pre-clinical arena

- Leveraging AI models in discovery will have to be a balance of opportunities and assessing the risks

- In-silico highlighted the huge opportunity of leveraging agile processes to rethink how pre-clinical work is being executed for faster iteration

- The combination of robotics and AI is extremely powerful, particularly when we think about the recent progress of humanoid robots that are being developed that could fit the often messy workflows of a lab better than the current stationary ones

- Data generation and knowledge management in the lab is still messy. Historical data often is dependent on what is stored in individual's memories. Therefore, Novartis has created a chatbot to be able to better access the institutional memory long what has been done in the past

- Furthermore, the long term effort of Data42 continues, the dedicated data platform that Novartis has been curating now for several years.

- Data organization and harmonization are essential to be able to generate insights but are still very much a challenge in the day to day workflows of the lab. It should be included by design from the start, to avoid garbage in / garbage out.